Have a personal or library account? Click to login
Curcumin-loaded nanostructured lipid carrier induced apoptosis in human HepG2 cells through activation of the DR5/caspase-mediated extrinsic apoptosis pathway Cover

Curcumin-loaded nanostructured lipid carrier induced apoptosis in human HepG2 cells through activation of the DR5/caspase-mediated extrinsic apoptosis pathway

Open Access
|Jan 2020

References

  1. 1 J. Bruix and M. Sherman, Management of hepatocellular carcinoma: An update, Hepatology53 (2011) 1020–1022; https://doi.org/10.1002/hep.2419910.1002/hep.24199308499121374666
  2. 2. U. Asghar and T. Meyer, Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J. Hepatol.56 (2012) 686–695; https://doi.org/10.1016/j.jhep.2011.07.03110.1016/j.jhep.2011.07.03121971559
  3. 3. S. R. Chen, H.C. Qiu, Y. Hu, Y. Wang and Y. T. Wang, Herbal medicine offered as an initiative therapeutic option for the management of hepatocellular carcinoma, Phytother. Res.30 (2016) 863–877; https://doi.org/10.1002/ptr.559410.1002/ptr.559426879574
  4. 4. B. Kocaadam and N. Sanlier, Curcumin, an active component of turmeric (Curcuma longa), and its effects on health, Crit. Rev. Food Sci. Nutr.57 (2017) 2889–2895; https://doi.org/10.1080/10408398.2015.107719510.1080/10408398.2015.107719526528921
  5. 5. H. Mahammedi, E. Planchat, M. Pouget, X. Durando, H. Cure, L. Guy, I. Van-Praagh, L. Savareux, M. Atger, M. Bayet-Robert, E. Gadea, C. Abrial, E. Thivat, P. Chollet and J. C. Eymard, The new combination docetaxel, prednisone and curcumin in patients with castration-resistant prostate cancer: A Pilot Phase II Study, Oncology90 (2016) 69–78; https://doi.org/10.1159/00044114810.1159/00044114826771576
  6. 6. W. Z. Wang, L. Li, M. Y. Liu, X. B. Jin, J. W. Mao, Q. H. Pu, M. J. Meng, X. G. Chen and J. Y. Zhu, Curcumin induces FasL-related apoptosis through p38 activation in human hepatocellular carcinoma Huh7 cells, Life Sci.92 (2013) 352–358; https://doi.org/doi:10.1016/j.lfs.2013.01.01310.1016/j.lfs.2013.01.01323352975
  7. 7. M. I. James, C. Iwuji, G. Irving, A. Karmokar, J. A. Higgins, N. Griffin-Teal, A. Thomas, P. Greaves, H. Cai, S. R. Patel, B. Morgan, A. Dennison, M. Metcalfe, G. Garcea, D. M. Lloyd, D. P. Berry, W. P. Steward, L. M. Howells and K. Brown, Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy, Cancer Lett.364 (2015) 135–141; https://doi.org/10.1016/j.canlet.2015.05.00510.1016/j.canlet.2015.05.005451014425979230
  8. 8. R. A. Sharma, S. A. Euden, S. L. Platton, D. N. Cooke, A. Shafayat, H. R. Hewitt, T. H. Marczylo, B. Morgan, D. Hemingway, S. M. Plummer, M. Pirmohamed, A. J. Gescher and W. P. Steward, Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance, Clin. Cancer Res.10 (2004) 6847–6854; https://doi.org/10.1158/1078-0432.CCR-04-074410.1158/1078-0432.CCR-04-074415501961
  9. 9. D. Ghosh, S. T. Choudhury, S. Ghosh, A. K. Mandal, S. Sarkar, A. Ghosh, K. D. Saha and N. Das, Nanocapsulated curcumin: oral chemopreventive formulation against diethylnitrosamine induced hepatocellular carcinoma in rat, Chem. Biol. Int.195 (2012) 206–214; https://doi.org/10.1016/j.cbi.2011.12.00410.1016/j.cbi.2011.12.00422197969
  10. 10. F. Wang, J. Chen, W. Dai, Z. He, D. Zhai and W. Chen, Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriers, Acta Pharm.67 (2017) 597–605; https://doi.org/10.1515/acph-2017-002110.1515/acph-2017-002128858837
  11. 11. F. Wang, Z. He, W. Dai, Q. Li, X. Liu, Z. Zhang, D. Zhai, J. Chen and W. Chen, The role of the vascular endothelial growth factor/vascular endothelial growth factor receptors axis mediated angiogenesis in curcumin-loaded nanostructured lipid carriers induced human HepG2 cells apoptosis, J. Cancer Res. Ther.11 (2015) 597–605; https://doi.org/10.4103/0973-1482.15908610.4103/0973-1482.159086
  12. 12. S. Fulda, Targeting apoptosis for anticancer therapy, Semin. Cancer Biol.31 (2015) 84–88. https://doi.org/10.1016/j.semcancer.2014.05.00210.1016/j.semcancer.2014.05.002
  13. 13. F. C. Kischkel, D. A. Lawrence, A. Chuntharapai, P. Schow, K. J. Kim and A. Ashkenazi, Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5, Immunity12 (2000) 611–620; https://doi.org/10.1016/s1074-7613(00)80212-510.1016/S1074-7613(00)80212-5
  14. 14. J. Chen, W. T. Dai, Z. M. He, L. Gao, X. Huang, J. M. Gong, H. Y. Xing and W. D. Chen, Fabrication and evaluation of curcumin-loaded nanoparticles based on solid lipid as a new type of colloidal drug delivery system, Indian J. Pharm. Sci.75 (2013) 178–184.
  15. 15. J. Li and J. Yuan, Caspases in apoptosis and beyond, Oncogene27 (2008) 6194–6206. https://doi.org/10.1038/onc.2008.29710.1038/onc.2008.29718931687
DOI: https://doi.org/10.2478/acph-2020-0003 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 227 - 237
Accepted on: Apr 19, 2019
Published on: Jan 16, 2020
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:

© 2020 Fengling Wang, Xi Ye, Dandan Zhai, Wenting Dai, Yifan Wu, Jin Chen, Weidong Chen, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.